MUNIT SA | Jetpharma | Microchem ads

The best time to think about particle size is before your first animal study. A scenario we see too often: a GLP tox study shows poor exposure. Investigation reveals the particle size was too large for adequate absorption. Now the team has to: → Re-micronize the batch → Run bridging studies → Repeat the tox study → Push the IND timeline by years All avoidable with one thing: a feasibility study at preclinical stage. At MUNIT, this typically includes: ✅ Small-quantity API assessment (a few grams) ✅ Milling trials to define target PSD ✅ Pre/post milling physical property analysis ✅ Recommendations for formulation path Low-cost, low-risk, and it de-risks everything downstream. Preparing for your first in-vivo study? This is the conversation to have now. Let's talk, start with a feasibility consultation. #Preclinical #DrugDevelopment #Formulation #Micronization #IND #CRO #EarlyPhase

Particle size can make or break your project. For many APIs, the right particle size distribution isn't optional; it determines #bioavailability, #dissolution, and whether your formulation works at all. Running a #FeasibilityStudy early, even with a small amount of powder, shows how your molecule behaves under real process conditions, before committing to a full-scale campaign. Our latest Technical Note explores how @Munit combines traditional experimental methods with computerized process simulation to predict #micronization outcomes faster, with minimum material consumption. Have a look to understand where micronization is heading, and why de-risking early is best practice.

Particle size can make or break your project. Download our Technical Note to see how Munit predicts micronization outcomes faster, with less material.

Some APIs don't behave well at room temperature, standard jet milling isn't enough, even though most compounds tolerate it fine. Exceptions: · Heat-sensitive APIs that degrade under milling · Waxy/sticky materials that agglomerate · Amorphous compounds needing controlled conditions · APIs requiring humidity control For these, cryogenic micronization is the answer: cooling the API and chamber with liquid nitrogen to: → Maintain crystal form → Prevent agglomeration → Achieve consistent particle size → Protect against polymorphic transformation MUNIT also offers Deep Cryogenic Milling and micronization at controlled temperature/humidity for tougher cases. Unusual physical properties are exactly when early process development matters most. Have a challenging API? Let's start with a feasibility consultation. #CryogenicMilling #Micronization #APIFormulation #HeatSensitive #ProcessDevelopment #Pharma #CDMO

Particle size can make or break your project. The right Particle Size Distribution determines bioavailability, dissolution, and whether your formulation works. Testing feasibility early, even with a small amount of powder, helps you de-risk before committing to full-scale production. Download our Technical Note to see how @Munit is combining traditional experimental methods with computerized simulation to predict micronization outcomes faster, with less material

Particle size can make or break your project. Download our Technical Note to see how Munit predicts micronization outcomes faster with less material.